RCVS is a disorder characterized by transient vasoconstriction of the cerebral arteries that resolves spontaneously. It can present with various neurological symptoms and can cause acute ischemic infarcts. Several drugs have been reported as potential RCVS triggers. Axitinib, a tyrosine kinase inhibitor that inhibits angiogenesis, is often combined with pembrolizumab, an immune checkpoint inhibitor, for treating renal cell carcinoma. Here, we report a case of RCVS potentially associated with Axitinib and Pembrolizumab therapy.
No takes yet. Share an insight, caveat, or question.
Bawaneh et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: